About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global Expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information ESG Contact us
Products Services
Product center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Career
Talent R&D Team Employee Life Job Opportunities
EN
CN
About Us
· Company Introduction · Strategic Development · Social Responsibility
Scientific Research
· Innovative Layout · Innovative Field
Products Services
· Product center · Product branding · Quality & Safety
News
· Company News · Media Coverage · Media Inquiries · Multimedia zone
Vocational
· Concept about Talent · R&D Team · Employee Life · Job Opportunities
> News > Company
Return
The Clinical Study in China of the Global Innovative RDC GPN02006 Achieved a Milestone Breakthrough
2025-04-22

The investigator-initiated clinical study (IIT clinical study) conducted in China of GPN02006, a global innovative radionuclide-drug conjugate (RDC) for diagnosis of hepatocellular carcinoma (HCC), has achieved a milestone breakthrough recently. The clinical results were published at the Chengdu 2025 Future XDC New Drug Conference.

Clinical study data show that GPN02006 exhibits excellent safety and imaging efficacy: all subjects did not report any drug related adverse reactions after administration, and the safety and tolerability were excellent; high quality imaging can be achieved 30 minutes after administration, fully meeting the clinical needs for rapid diagnosis of hepatocellular carcinoma.

The product has three significant advantages in imaging quality: extremely low background signal; high uptake specific to HCC lesions; and excellent diagnostic contrast. Based on its unique molecular targeting mechanism, the product can achieve: early and precise localization of HCC lesions; dynamic evaluation of treatment response; and early warning of recurrence and metastasis.

Prev

Next

Related news

  • Update on Strategic Investment in Telix
    Update on Strategic Investment in Telix

    2025-03-01

  • The Clinical Study in China of the Global Innovative RDC GPN02006 Achieved a Milestone  Breakthrough
    The Clinical Study in China of the Global Innovative RDC GPN02006 Achieved a Milestone Breakthrough

    2025-04-22

  • 2024 Grand Pharma Annual Report
    2024 Grand Pharma Annual Report

    2025-05-06

Grand Pharma Group
About Us
Company Introduction Strategic Development Social Responsibility
Scientific Research
Innovative Layout Innovative Field
International
Global expansion Cooperative Partner Global R&D Centers International Cooperation
Investor Relations
Information Disclosure Corporate Governance Stock Information Contact us
Products Services
Product Center Product branding Quality & Safety
News
Company News Media Coverage Media Inquiries Multimedia zone
Vocational
Concept about Talent R&D Team Employee Life Job Opportunities
Copyright © Grand Pharma (China) Co., Ltd. All Rights Reserved E ICP B 10008288 EGWAB 42010402000597
Legal Provisions